Full-Time

Senior Manager

Hyperfine

Hyperfine

51-200 employees

Portable bedside MRI system for hospitals

Compensation Overview

$162k - $186k/yr

+ Bonus + Equity

No H1B Sponsorship

Palo Alto, CA, USA + 1 more

More locations: Branford, CT, USA

Hybrid

Hybrid role requiring 3 days on-site per week; eligible locations Guilford, CT or Palo Alto, CA.

Category
Legal & Compliance (1)
Required Skills
FDA Regulations
Risk Management
Requirements
  • Bachelor’s degree required (scientific/engineering discipline preferred) with 15+ years of progressive regulatory affairs experience in medical devices; or Master’s degree with 10+ years of progressive regulatory affairs experience
  • Significant hands-on ownership of U.S. and international submissions and post-market change management
  • Demonstrated success leading U.S. and OUS submissions and sustaining activities for Class I and Class II medical devices (preferably imaging/MRI), including managing questions/deficiencies to clearance/approval
  • Strong working knowledge of FDA regulations and expectations (e.g., 21 CFR 807/820, 21 CFR 801), ISO 13485, MDSAP, and global regulatory frameworks (e.g., EU MDR, UKCA, Health Canada)
  • Proven ability to lead cross-functional teams through complex regulatory deliverables with clear ownership, on-time execution, and sound judgment balancing speed and compliance
  • Deep experience interpreting and applying FDA guidance, recognized standards, and international requirements; able to translate requirements into clear plans and document-ready content
  • Strong regulatory strategy skills, including pathway assessment, predicate/device comparisons, intended use/indications development, and lifecycle change impact assessments
  • Experienced directly interacting with FDA and international regulators/Notified Bodies, including leading meetings, preparing briefing packages, and managing written responses
  • Excellent written and oral communication skills including the ability to interact with all levels of the company
  • Excellent ability to read, analyze and interpret technical documents, professional journals, technical procedures, and regulations
  • Ability to work independently with minimal supervision while keeping stakeholders aligned through clear, concise updates and proactive risk escalation
Responsibilities
  • Develop and lead regulatory strategies for Class I devices and Class II MRI devices to enable timely U.S. clearance and global market access in alignment with business priorities
  • Define submission plans, timelines, and resourcing; drive cross-functional readiness in a start-up environment with shifting priorities and accelerated schedules
  • Lead preparation, publishing, and maintenance of regulatory submissions (e.g., FDA 510(k)s, Q-Sub/Pre-Sub interactions as needed, and international registrations such as EU MDR/UKCA, Canada, Australia, and other priority markets), ensuring completeness and compliance with applicable requirements
  • Support product development by guiding teams on regulatory requirements and expectations, including design controls, risk management, software/cybersecurity considerations (as applicable), MRI-related standards, clinical evidence planning, and review of labeling and promotional claims
  • Build and scale regulatory infrastructure (SOPs, templates, submission archives, and decision records) that enables consistent execution and inspection/audit readiness as the organization grows
  • Partner with Quality to support external audits and inspections (e.g., ISO 13485/MDSAP, FDA) and to maintain alignment between regulatory commitments and the QMS
  • Review and approve labeling, instructions for use, and commercial materials for regulatory compliance (U.S. and international), ensuring claims are accurate, substantiated, and aligned to cleared/approved indications
  • Serve as a primary point of contact with global regulatory agencies and Notified Bodies; lead meeting preparation, responses to questions/deficiencies, and negotiation of clear regulatory pathways
  • Recruit, hire, coach, and develop regulatory personnel; effectively select and manage external consultants, testing labs, and submission publishing partners to meet program needs
Desired Qualifications
  • Experience in Research & Development (R&D)
  • Familiarity with AI-based software, medical imaging, active devices

Hyperfine creates medical imaging tools for hospitals, focusing on the Swoop system, the first FDA-cleared portable ultra-low field MRI that can image a patient’s brain at the bedside. How it works: a compact, portable MRI device is brought to the patient in settings like intensive care units, performing brain scans without moving the patient to a radiology suite. The open, safe design allows family members to stay nearby during imaging. Differentiation: it is already FDA-cleared and designed for point-of-care use, enabling bedside decision-making, faster treatment decisions, quicker discharges, and more efficient use of hospital staff and resources at a lower cost compared to traditional MRI workflows. Revenue model: Hyperfine sells the Swoop system and related services to hospitals, clinics, and other healthcare facilities. Goal: improve patient care by bringing diagnostic imaging directly to patients, increasing access to timely brain imaging and streamlining clinical workflows.

Company Size

51-200

Company Stage

IPO

Headquarters

Guilford, Connecticut

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue surged 83% to $3.9M from next-gen Swoop sales.
  • NVIDIA March 2026 collaboration accelerates AI image reconstruction and scan times.
  • $3.7M Gates Foundation grant funds neonatal imaging in low-resource settings.

What critics are saying

  • GE Healthcare and Siemens launch competing ultra-low field MRIs within 12-24 months.
  • $40.8M cash lasts to late 2027 without profitability or new funding.
  • Horizon $40M loan's 10.75% interest and warrants dilute equity immediately.

What makes Hyperfine unique

  • Swoop system delivers first FDA-cleared portable ultra-low field MRI for bedside brain imaging.
  • Optive AI software upgrade cleared December 2025 enhances stroke detection via multi-direction DWI.
  • Open design allows family presence during ICU scans, unlike traditional high-field MRIs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Hyperfine who can refer or advise you

Benefits

Remote Work Options

Hybrid Work Options

Wellness Program

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
The Associated Press
Apr 9th, 2026
Hyperfine wins CE and UKCA marks for next-gen Swoop MRI system and Optive AI software

Hyperfine has received CE marking and UK Conformity Assessment approval for its next-generation Swoop portable MRI system and latest Optive AI software, enabling commercialisation across Europe and the UK. The approvals mark a key milestone in the company's international growth strategy. The next-generation Swoop system, FDA-cleared in Q2 2025, delivers improved image quality and workflow for brain imaging. The updated Optive AI software includes multi-direction diffusion-weighted imaging capabilities, enhancing stroke detection similar to high-field MRI scanners. The technology is currently distributed across over a dozen European countries through Hyperfine's network. The company plans to begin commercialisation of the new system and software in Europe and the UK in early Q3 2026, ahead of internal expectations.

Yahoo Finance
Mar 19th, 2026
Hyperfine reports $5.3M Q4 revenue, up 128%, targets $21M in 2026 with 50%+ margins

Hyperfine Inc reported record fourth-quarter revenue of $5.3 million, up 128% year-over-year, driven by strong performance of its next-generation Swoop scanner. The medical imaging company sold 16 units in Q4, compared to nine units in the prior-year period. Gross margin expanded to 50.9%, up 1,530 basis points from Q4 2024, whilst net loss narrowed to $5.9 million from $10.4 million. Full-year 2025 revenue reached $13.6 million, up 5% from 2024. The company received FDA clearance for updated Optive AI software and gained approval for its first-generation Swoop system in India. Hyperfine reduced cash burn by 30% year-over-year to $5.7 million. For 2026, the company projects revenue of $20 million to $22 million, representing 55% growth at the midpoint, with gross margins of 50% to 55%.

Yahoo Finance
Mar 18th, 2026
Hyperfine reports $5M Q4 revenue as portable brain MRI gains traction in hospitals

Hyperfine reported fourth-quarter revenue exceeding $5 million, driven by accelerating adoption of its second-generation Swoop portable brain MRI system and Optive AI software. CEO Maria Sainz described the combination as a "market turning point" for portable brain MRI, highlighting diagnostic-quality imaging from ultra-low field magnets. The company has sold over a dozen next-generation systems since June 2025, focusing on critical care, emergency departments and neurology offices. The FDA cleared a software update in December 2025 featuring diffusion-weighted imaging for stroke workflows. Hyperfine cited external validation including published health economic data from Jefferson Abington Hospital showing cost savings across 143 scans. Yale School of Medicine's PRIME study evaluating AI-powered portable MRI in emergency departments completed enrollment ahead of schedule, with results expected later in 2026.

Stock Titan
Mar 18th, 2026
Hyperfine (NASDAQ: HYPR) adds $40M loan facility and over 1.0M stock warrants

Hyperfine arranged a $40M senior secured loan with Horizon, drawing $15M initially, at a minimum 10.75% rate and issuing over 1.0M stock warrants at $1.20 per share.

Business Wire
Nov 20th, 2025
Hyperfine Awarded $3.7 Million Grant to Advance Global Brain Health

$3.7M grant supports expanded use of portable MRI to evaluate brain development and guide targeted health interventions in underserved communities.